efferon-ct-2024-02
Проводит Efferon JSC
Страница компанииA Randomised Pilot Study of the Efficacy and Safety of Using Hemoperfusion With Efferon CT to Treat Patients With Severe Psoriasis
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT06640114/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 60 чел. во всех странах исследования.
- Центров в реестре: 2 в одном городе. Список — ниже на странице.
- Плановая дата окончания (07.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 14
Критерии включения
- ability to provide written informed consent and willingness and ability to comply with all requirements of the clinical trial design.
- 18 to 70 years of age.
- moderate to severe psoriasis (plaque psoriasis without psoriatic arthritis) with a disease duration of at least 6 months.
- should be receiving standard psoriasis therapy according to clinical recommendations (topical therapy, systemic therapy, phototherapy).
- Psoriasis Area and Severity Index (PASI) score ≥10,
- Body surface area (BSA) affected by psoriasis ≥10%,
- Dermatology Life Quality Index (DLQI) score >10 points,
- physician's global assessment of psoriasis severity using the static Physician Global Assessment (sPGA) ≥3 points,
- Dermatological Disease Severity Index (DIDS) score ≥2.
- for female patients: postmenopausal or have a negative pregnancy test (urinalysis) prior to enrolment. If urinalysis does not confirm absence of pregnancy, an appropriate serum analysis should be performed. The subject's pregnancy test must be negative to be eligible for inclusion in the study.
Критерии невключения
- patients with other forms of psoriasis (e.g. psoriatic erythroderma, pustular psoriasis, scale psoriasis, psoriatic arthritis) or other skin conditions (e.g. eczema).
- patients on genetically engineered biological therapy (GEBT) for psoriasis.
- patients with mild forms of psoriasis.
- patients with HIV infection, syphilis, acute infectious diseases, tuberculosis.
- patients with oncological diseases.
- patients with chronic diseases in the stage of decompensation.
- patients with thrombosis and recurrent thromboembolism, thrombophlebitis.
- female patients who are pregnant or breastfeeding.
- age of patients younger than 18 years and older than 70 years.
- in the opinion of the investigator, inability of the subject to participate in this study for any other reason.
- mental condition in which the subject is unable to understand the nature, purpose and possible implications of this research.
- history of allergy, hypersensitivity to components of the extracorporeal circuit.
- inability or unwillingness to undergo all follow-up procedures until the end of the study and/or unwillingness to allow access to their medical records in accordance with national regulatory requirements at the time of consent.
- Charlson Index score greater than 6.
Источник: ClinicalTrials.gov, NCT06640114 · запись обновлена в реестре 24 ноября 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 4
- Change in PASI (Psoriasis Area and Severity Index) score — 0 - 90 days
- Change in BSA (Body surface area) score — 0 - 90 days
- Change in the Dermatology Life Quality Index (DLQI) score — 0 - 90 days
Цель исследования
Psoriasis is a chronic, inflammatory skin condition driven by the immune system, marked by red, scaly plaques that commonly affect the scalp and nails. About 30% of psoriasis patients may develop psoriatic arthritis, especially those with severe psoriasis or lesions on the nails or scalp. Research has identified distinct cytokine gene expression patterns in skin versus synovial tissue, which may explain the differing responses to biologic therapies in these areas. Factors such as genetic predisposition, infections, obesity, and biomechanical stress can trigger disease onset, leading to the release of cytokines that activate both the innate and adaptive immune responses. This immune activation can cause synovitis, enthesitis, erosions, and lesions in both articular cartilage and skin.
Given the reviewed literature and evidence that hemoperfusion with Efferon CT can non-specifically adsorb excess cytokines and inflammatory mediators, our research team hypothesizes that cytokine sorption could have beneficial clinical effects for patients with severe and moderate psoriasis. This study aims to evaluate the efficacy and safety of anticytokine hemoperfusion using the Efferon CT device for treating these patients.
Где проходит
2 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06640114 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.